Indications for CYTOMEL:
Hypothyroidism: initially 25mcg daily; may increase by up to 25mcg every 1–2 weeks; usual maintenance 25–75mcg daily. Myxedema, simple goiter: initially 5mcg daily; may increase by 5–10mcg daily every 1–2 weeks to 25mcg daily, then may increase by 5–25mcg every 1–2 weeks (myxedema) or by 12.5 or 25mcg daily every 1–2 weeks (simple goiter). Maintenance: myxedema: 50–100mcg/day; simple goiter: 75mcg/day.
Initially 5mcg daily; may increase by 5mcg daily every 3–4 days. Cretinism: maintenance dose: <1yr: 20mcg/day. 1–3yrs: 50mcg/day. >3yrs: as adult.
Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis.
Larger doses particularly when given concomitantly with sympathomimetic amines for anorectic effects may produce serious or life-threatening toxicity.
Not for treatment of obesity or infertility (unless with hypothyroidism). Cardiovascular disease, angina, elderly: use lower initial dose. Adrenocortical insufficiency. Diabetes. Monitor for craniosynostosis in infants. Pregnancy (Cat.A). Nursing mothers.
Monitor oral anticoagulants, hypoglycemics, digoxin. Estrogens affect thyroid function tests. Monitor for hypertension with ketamine. Toxicity with larger doses of sympathomimetics (eg, anorectics).
Hyperthyroidism, transient hair loss in children.